Live Breaking News & Updates on ஜுவ் தகவல்தொடர்புகள்

Stay updated with breaking news from ஜுவ் தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |SDI Group PLC Announcements | SDI Group PLC: Director Dealing


A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
1. Obtains access to the information in a personal capacity;
2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so; ....

United Kingdom , City Of , Julia Wilson , Jon Abell , Ed Frisby Kate Bannatyne , Andrew Burdis Sunila , Ken Ford , Mike Creedon , Company Ordinary , London Stock Exchange , Cap Ltd , Mintonview Ltd , European Union Withdrawal , Jw Communications , Sdi Group , Abuse Regulation , Kate Bannatyne , Sunila De Silva , Atik Cameras , Graticules Optics , Astles Control Systems , Applied Thermal Control , Chell Instruments , Market Abuse Regulations , European Union , Stock Exchange ,

Mestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer


Published: Apr 21, 2021
- Backed by leading healthcare investors including SV Health Investors -
Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”).
The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and im ....

United States , United Kingdom , Mark Coles , Davida Tuveson , Michael Brenner , Soumya Raychaudhuri , Julia Wilson , Sanofi Aventis , Phouman Ashrafian , Susan Hill , Chris Buckley , Michaelb Brenner , David Tuveson , Research Early Development , Sv Health Investors , Kennedy Institute Of Rheumatology , Lustgarten Foundation , Jjdc Inc , Musculoskeletal Sciences , University Of Oxford , Cancer Center , Nuffield Department Of Orthopaedics , Head Of Group Finance At Horizon Discovery , Infrastructure For Birmingham Health Partners , Jw Communications , Research Crescendo Biologics ,